Trades on 1 secondary market

Granza Bio

Granza Bio is an early-stage biotechnology company reprogramming immunity for target-specific medicines. Founded in 2024 by Dr. Ashwin Nandakumar, Dr. Ashwin Jainarayanan, and Prof. Michael Dustin, the company builds on the discovery of "attack particles" — killing entities released by cytotoxic imm

minimal 11.2 / 100 0 APIs View provider profile →

Company Biotechnology Immunotherapy Drug Delivery Life Sciences Oncology

Granza Bio is an API provider whose private shares are listed on 1 secondary market: Nasdaq Private Market.

Where It Trades

N Nasdaq Private Market View listing →

Listing data is compiled from the public marketplace pages of Forge Global, Hiive, EquityZen, Nasdaq Private Market, and Augment. A listing indicates that a venue has published a page for this company — it is not an offer, a quote, or investment advice, and APIs.io has no affiliation with any venue.